Biotech startup METiS Therapeutics plans Hong Kong IPO with AI-driven drug delivery revolution
By Da Cheung METiS Therapeutics, a drug discovery and delivery biotech, has received the regulatory green light…
Behind the frenzy for Yangtze Memory’s unlisted shares ahead of its IPO
By Wang Manhua Lately, Wang Tao (a pseudonym) hasn’t had a moment’s peace. Every day, investors…
Three Chinese hard-tech firms, including Extreme Vision, pass Hong Kong listing hearings
By Stone Jin A flurry of pre-IPO activity has taken place on the Hong Kong Stock…
From vacuum cleaners to space tech: Dreame’s ambitious pivot to an AI ecosystem
By Da Cheung At the AWE 2026 Chip Industry Summit in Shanghai, household appliance manufacturer Dreame Technology signaled…
Baidu set for a valuation upgrade as strength of AI business is revealed
By Beilong Industry Research Baidu’s (9888.HK) fourth quarter and full-year financial report, released on Feb. 26,…
Latest
- Han’s CNC rides AI infrastructure boom, but expansion brings new risks
- China demonstrates novel net-catch rocket recovery system as it races to close the gap with SpaceX
- China turns to molten salt to tackle renewable energy storage bottlenecks in the national grid
- Dramatic slowdown in China’s range-extended electric vehicle market raises concerns over Xiaomi’s strategy
- Biokin’s new cancer drug secures historic approval in China, but Western regulatory hurdles loom
